Inotiv Executive and Leadership Team

Robert Leasure, the Chief Executive Officer & President at Inotiv, directs the overarching corporate strategy and long-term vision for the organization. Overseeing the integration of scientific capabilities across the drug discovery continuum, the Chief Executive Officer & President ensures that every client program receives attentive and decisive service. This leadership role involves managing the company's regulatory history and maintaining high standards for data delivery across global markets. By aligning the world-class team of scientists with the broader business objectives, Robert Leasure drives the expansion of research model supply and CRO services. The Chief Executive Officer & President maintains focus on delivering a superlative experience for partners from initial discovery through the IND phase. Ultimately, Leasure secures the company's position as a right-sized partner for complex pharmaceutical projects while fostering sustainable growth and operational excellence across all business units.

Greg Beattie, the Chief Operating Officer at Inotiv, manages the daily execution of scientific operations and service delivery across the organization. Overseeing the infrastructure required for research model supply and CRO projects, the Chief Operating Officer ensures that all laboratory processes meet rigorous quality standards. This leadership role involves optimizing the workflow for rodents, rabbits, and nonhuman primates to guarantee on-time data delivery for clients. By coordinating resources across North American facilities, Greg Beattie drives operational efficiency and maintains the integrity of the research continuum. The Chief Operating Officer collaborates with the executive team to scale internal capabilities in response to evolving market demands. Through the implementation of standardized protocols, Beattie ensures that every project receives the necessary scientific support. Ultimately, the Chief Operating Officer strengthens the company's reputation for reliability and precision in the competitive research services landscape.

Lizanne Muller, the Group President, RMS at Inotiv, manages the strategic direction and operational performance of the Research Model Services division. Overseeing the supply chain and production of critical research models, the Group President, RMS ensures that the company meets the specific needs of the global scientific community. This leadership role involves maintaining the highest standards for animal welfare and model quality to support the drug discovery continuum. By driving initiatives to expand the availability of rodents, rabbits, and nonhuman primates, Lizanne Muller ensures that researchers have access to the essential tools for their projects. The Group President, RMS collaborates with the broader executive team to integrate model supply with CRO services for a seamless client experience. Through the optimization of production facilities, Muller supports the company's commitment to on-time delivery. Ultimately, the Group President, RMS secures the company's leadership in the research model market.

Alison Bendele, the Founder and President of Bolder BioPATH at Inotiv, directs the specialized pathology and pharmacology research services that enhance the company's CRO capabilities. Overseeing the execution of complex preclinical studies, the Founder and President of Bolder BioPATH ensures that clients receive precise, actionable data for their drug development programs. This leadership role involves applying deep scientific expertise to solve unique challenges in the discovery phase. By integrating specialized pathology insights into the broader Inotiv service offering, Alison Bendele drives the delivery of high-value research outcomes. The Founder and President of Bolder BioPATH collaborates with other scientific leaders to maintain the company's reputation for excellence in the IND process. Through the management of specialized laboratory operations, Bendele ensures that every project benefits from rigorous scientific scrutiny. Ultimately, the Founder and President of Bolder BioPATH strengthens the company's ability to support clients from initial discovery through advanced development.

Becky Dolliver, the Chief Information Officer at Inotiv, architects the digital framework and data management systems supporting the company's scientific research. Overseeing the security and accessibility of critical research data, the Chief Information Officer ensures that all digital platforms align with regulatory requirements and client needs. This leadership role involves integrating advanced technology solutions to streamline the drug discovery process and enhance the delivery of quality data. By modernizing the IT infrastructure, Becky Dolliver drives the digital transformation necessary for scaling CRO operations across diverse geographic regions. The Chief Information Officer collaborates with scientific teams to implement robust data analytics tools that support informed decision-making. Through the protection of proprietary research information, Dolliver maintains the trust of partners throughout the IND development phase. Ultimately, the Chief Information Officer secures the technological foundation required for the company's continued innovation and operational success.

Jeff Krupp, the Chief Human Resources Officer at Inotiv, directs the talent acquisition and organizational development strategies necessary to support a world-class team of scientists. Overseeing the recruitment of specialized personnel, the Chief Human Resources Officer ensures that the company maintains the deep expertise required for complex drug discovery projects. This leadership role involves fostering a culture of attentive service and professional excellence across all departments. By implementing comprehensive training and retention programs, Jeff Krupp drives the growth of the workforce to meet the demands of the research model and CRO sectors. The Chief Human Resources Officer collaborates with leadership to align human capital strategies with the company's long-term business goals. Through the management of employee engagement and performance initiatives, Krupp supports the delivery of high-quality scientific outcomes. Ultimately, the Chief Human Resources Officer builds the organizational capacity needed to sustain the company's market position.